DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Brown Advisory Inc.

Brown Advisory Inc. grew its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 261,774 shares of the medical device company's stock after buying an additional 46,454 shares during the quarter. Brown Advisory Inc. owned 0.07% of DexCom worth $17,877,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Proficio Capital Partners LLC acquired a new position in DexCom during the 4th quarter worth $5,812,000. Golden State Wealth Management LLC grew its stake in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares in the last quarter. Farther Finance Advisors LLC grew its stake in DexCom by 29.3% during the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after purchasing an additional 702 shares in the last quarter. Private Trust Co. NA grew its stake in DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after purchasing an additional 335 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC grew its stake in DexCom by 34.2% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after purchasing an additional 1,333 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DexCom stock traded down $2.09 on Friday, hitting $83.37. The stock had a trading volume of 2,309,390 shares, compared to its average volume of 4,433,737. The stock has a market cap of $32.69 billion, a price-to-earnings ratio of 62.22, a P/E/G ratio of 1.78 and a beta of 1.44. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.19. The company's 50 day moving average price is $84.35 and its 200 day moving average price is $79.99. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business's revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 EPS. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In related news, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director owned 56,621 shares in the company, valued at $4,706,903.73. The trade was a 4.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president owned 95,602 shares in the company, valued at $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,190 shares of company stock worth $2,281,732. Insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Citigroup reaffirmed a "buy" rating and set a $102.00 price target (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Robert W. Baird decreased their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Piper Sandler decreased their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $98.50.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.